Fast Five Quiz: Type 2 Diabetes and Cardiovascular Disease Risk

Romesh Khardori, MD, PhD


January 14, 2021

Current guidelines report that CVD risk ≥ 20% in patients with diabetes is considered a CVD risk equivalent. For these patients, the same high-intensity statin therapy is recommended as for those with existing CVD. Informed by recent clinical trials that have evaluated the efficacy of combining of statin and nonstatin therapy, the ADA recommends that it may also be appropriate to add additional cholesterol-lowering therapy to maximally tolerated statin therapy.

High-intensity statins are typically reserved for individuals with overt CVD (including previous cardiovascular events or acute coronary syndrome) and/or CVD risk factors. Moderate-intensity statins are recommended for the majority of patients with diabetes.

Control of hypertension is an important strategy for CVD risk reduction among individuals with T2D. Randomized clinical trials have clearly shown that treatment of hypertension to blood pressure < 140/90 mm Hg reduces both cardiovascular events and microvascular complications.

Although patients with T2D commonly have elevated triglycerides, whether or not therapy to reduce triglycerides lowers risk of CHD events warrants further research.

Learn more about cardiovascular risk reduction in individuals with T2D.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: